ELISA/assay

Porcine c-myc Oncogene product ELISA Kit

MBS737188

48-Strip-Wells

470 USD

ELISA Kit

Porcine c-myc Oncogene product ELISA Kit

c-myc Oncogene product

c-myc, partial; C-myc protein; myc proto-oncogene protein; proto-oncogene c-Myc; transcription factor p64; class E basic helix-loop-helix protein 39; avian myelocytomatosis viral oncogene homolog; v-myc myelocytomatosis viral oncogene homolog; myc-related translation/localization regulatory factor; v-myc avian myelocytomatosis viral oncogene homolog; C-myc protein

C-MYC

MYC; c-myc; MRTL; MYCC; c-Myc; bHLHe39

Q6LBK7_HUMAN

Porcine

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This Cmyc ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Porcine Cmyc. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cancer

Principle of the Assay: C-MYC ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-C-MYC antibody and an C-MYC-HRP conjugate. The assay sample and buffer are incubated together with C-MYC-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the C-MYC concentration since C-MYC from samples and C-MYC-HRP conjugate compete for the anti-C-MYC antibody binding site. Since the number of sites is limited, as more sites are occupied by C-MYC from the sample, fewer sites are left to bind C-MYC-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The C-MYC concentration in each sample is interpolated from this standard curve.

396512

CAA46984.1

Q6LBK7

7,012 Da

Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); Apoptosis Pathway (198797); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); C-MYB Transcription Factor Network Pathway (138073); C-MYC Pathway (169344); CD40/CD40L Signaling Pathway (138061); Cell Cycle Pathway (530733); Cell Cycle, Mitotic Pathway (105765)

The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. [provided by RefSeq, Jul 2008]

Myc: a proto-oncogenic transcription factor that plays a role in cell proliferation, apoptosis and in the development of human tumors. Seems to activate the transcription of growth-related genes. Protein type: DNA-binding; Nucleolus; Oncoprotein; Transcription factor. Chromosomal Location of Human Ortholog: 8q24.21. Cellular Component: nucleoplasm; protein complex; nucleolus; nucleus; cytosol. Molecular Function: protein dimerization activity; protein binding; DNA binding; protein complex binding; transcription factor binding; transcription factor activity. Biological Process: cellular iron ion homeostasis; oxygen transport; positive regulation of transcription, DNA-dependent; positive regulation of caspase activity; negative regulation of transcription from RNA polymerase II promoter; Wnt receptor signaling pathway through beta-catenin; chromosome organization and biogenesis; positive regulation of fibroblast proliferation; transforming growth factor beta receptor signaling pathway; positive regulation of cell proliferation; positive regulation of mesenchymal cell proliferation; response to gamma radiation; cell cycle arrest; response to drug; transcription initiation from RNA polymerase II promoter; Notch signaling pathway; transcription, DNA-dependent; regulation of telomere maintenance; MAPKKK cascade; negative regulation of cell division; negative regulation of monocyte differentiation; negative regulation of stress-activated MAPK cascade; chromatin remodeling; negative regulation of fibroblast proliferation; ureteric bud branching; regulation of gene expression; energy reserve metabolic process; gene expression; positive regulation of transcription from RNA polymerase II promoter; response to DNA damage stimulus; positive regulation of epithelial cell proliferation; negative regulation of apoptosis. Disease: Burkitt Lymphoma

48-Strip-Wells

470 USD

96-Strip-Wells

675